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ANXIOLYTIC EFFECT OF MIDAZOLAM PREMEDICATION ASSESSED
BY CLINICAL AND PLATELET AGGREGATION PROFILES
Ehtesham I. Khan, Rehana S. Kamal, Hameed Ullah
Department of Anaesthesia & Intensive Care, Aga Khan University, Karachi, Pakistan

Background: It is well documented that surgery is associated with increased anxiety, which has an
adverse impact on patient’s outcome. This study was designed to assess the anxiolytic effect of
midazolam in pre-anaesthetic medication by using clinical and platelet aggregation profiles.
Methods: Sixty ASA I and II female patients aged between 35 and 60 years undergoing elective
abdominal hysterectomy were randomly divided into two equal groups. Group I received placebo as
pre-medication while group II received 0.15 mg/kg midazolam as pre-medication 1 hour
preoperatively. They were monitored for visual analogue scale (VAS) for anxiety, observer’s anxiety
criteria, sedation score, blood pressure, heart rate and platelet aggregation profile immediately before
and 1 hour after pre-medication. Results: There was statistically significant difference with respect
to VAS of anxiety, observer’s anxiety criteria, sedation scores, systolic and diastolic blood pressure
(p<0.05). Heart rate was higher in the midazolam group but this was not statistically significant.
There was no statistical significant difference in platelet aggregation profile in the two groups.
Conclusion: Findings of the study suggest midazolam is a good anxiolytic for pre-medication and its
effect on platelet aggregation profile needs to be further evaluated.
Keywords: Pre-medication, Widazolam, Anxiolysis, Platelet aggregation

INTRODUCTION
Preoperative anxiety is a challenging concept in the
preoperative care of patients and almost all patients
undergoing surgery experience varying level of
anxiety.1 Anxiety is dependant upon the perceived
threat and danger of the surgical procedure, pain,
anaesthesia, outcome of surgery and worries about the
family. Patients undergoing major surgery, i.e., major
abdominal, thoracic and cardiac surgery and women
have higher levels of anxiety.2 It has been
demonstrated that women undergoing invasive
radiological or surgical procedures for gynaecological
disorders experience higher levels of state anxiety,
express more worry, display greater heart rate and
blood pressure changes before and during surgery, are
more difficult to anaesthetise and are more likely to
experience headache, vomiting and pain in the
postoperative period.3,4 Relief of anxiety is thus a
humane goal and should be attempted in every patient.
Benzodiazepines are widely used as
anxiolytics prior to surgery.5 Midazolam, a water
soluble benzodiazepine is a useful agent for
pre-medication and sedation. It has a short onset time
and duration of action when compared to other
benzodiazepines. In addition to anxiolysis, it also
possesses hypnotic, anticonvulsant, muscle relaxant
and antegrade amnestic properties.6
Blood platelets, numbering 1.8–3.5×105/ml,
circulate within the vasculature as disc shaped cells
that are normally non-adherent to each other and to the
endothelial cells that line the blood vessel wall.
‘Platelet aggregation’ is a term used to denote the
adherence of one platelet to another. Adding
aggregating agent, e.g., adrenaline, noradrenaline, etc.
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to platelet rich plasma, which is being continually
stirred, can induce this phenomenon. Induction of
platelet aggregation by adrenaline presumably occurs
through binding to specific receptor, suggested to be
α-type, on platelet membrane.7
Preoperative anxiety is associated with a rise
in plasma catecholamine (adrenaline, noradrenaline)
levels. This rise in adrenaline would result in
enhanced platelet aggregation in anxiety states.
Midazolam, an anxiolytic agent, would reduce the
anxiety levels and corresponding catecholamine
secretion. This will prevent the platelet aggregation
in patients receiving midazolam as pre-medication.
The objective of this study was to examine the
anxiolytic effects of midazolam in a homogenous group
of patient undergoing elective hysterectomy using
cardiovascular variables, subjective anxiety and sedation
scores and objectively by platelets aggregation profiles.

MATERIAL AND METHODS
After approval from Ethics Review Committee of the
Aga Khan University and obtaining informed consent,
a double blinded, randomized, placebo controlled
trial was conducted on 60 ASA I and II female
patients, aged between 35 and 60 years, scheduled for
elective abdominal or vaginal hysterectomy. Patients
with history of psychiatric illness, alcohol abuse,
hypertension, ischemic heart disease, diabetes
mellitus, patients receiving β-blockers and Ca++
channel blockers and those taking benzodiazepines
since admission to hospital were excluded from the
study. Patients were equally divided into two groups
with patients in group I receiving placebo and
group-II receiving midazolam 0.15 mg/kg orally as
pre-medication 1 hour prior to the anaesthetic. The
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pre-medication drug, either placebo or midazolam,
was grinded and dissolved in sweet syrup to make the
drug palatable. The final concentration of midazolam
was 1 mg/ml and the mixture was prepared fresh for
every patient. Appropriate amount of drug was given
to the patient in the ward by a person not involved in
taking observations.
Following parameters were monitored
immediately before and 1 hour after the
administration of study drug:
1 Visual analogue scale for anxiety in which
patients were asked to grade their level of anxiety
on a scale of 0–10 (0 being totally calm and 10
being extremely anxious).
2 Observer’s anxiety criteria, in this, the patient’s
anxiety was assessed by the observer who was
blinded to the type of medication given to the
patient and was assessed on the following scale:
Grade 1- Calm
Grade 2- Mild anxiety
Grade 3- Moderately anxious
Grade 4- Extremely anxious.
3 Sedation score was also assessed by the blinded
observer who rated the patients sedation as:
Grade 0: Fully awake,
Grade 1: Awake but with signs of drowsiness,
Grade 2: Asleep but responsive to spoken words,
Grade 3: Asleep and unresponsive to spoken
words and
Grade 4: Asleep and unresponsive to gentle
shaking.
4 Systolic and diastolic blood pressure and heart
rate was measured by using automated blood
pressure and heart rate monitors.
5 For platelet aggregation profile, the method used to
quantitatively assess platelet aggregation was
introduced by Born8 in 1962 and is based on the
principle of light transmission through platelets rich
plasma (PRP) caused by the formation of platelet
aggregates and the volume occupied by the platelets
in a photoelectric cell. In this study, 4.5 ml of
venous blood was collected in a 5 ml syringe with a
21 gauge needle. Blood was then gently transferred
into a tube containing 0.5 ml of 3.8% sodium citrate
which was mixed by gentle inversion and vigorous
shaking was avoided. This process was done before
and one hour after the pre-medication. The sample
was taken to the pharmacology laboratory and PRP
was prepared by centrifuging the sample at a speed
of 1,100–15,000 RPM for 15 minutes (DYDAC II
Clay Adams). PRP was withdrawn with a
siliconised plastic pipette into a glass tube and was
capped and labelled PRP. The platelet poor plasma
(PPP) was prepared by re-centrifuging the
remaining blood specimen at 4,000 RPM for 5
minutes. The PPP was transferred into a plastic tube

and was labelled platelet poor plasma. To study
platelet aggregation Lumi Aggregometer model
400 was used. Epinephrine 200 mol was added
to 0.45 ml of PRP, which was continually being
stirred. As aggregation proceeded, platelet
clumping occurred. This reduced the optical density
of the PRP allowing more infrared light to pass
through. The process was repeated for PPP. The
Lumi
Aggregometer
developed
voltage
proportional to the difference between the PRP and
PPP and this difference was recorded on the strip
chart. Test was performed within an hour after the
blood was drawn from the patient and efforts were
made to keep the plasma at ambient temperature of
37 ºC.
All values given in the results are presented
as mean with standard deviation (SD). Numerical
data were analysed using the analysis of variants
(ANOVA) and chi-square test where appropriate. A
p-value of less than 0.05 was considered statistically
significant in each case.

RESULTS
Both the groups were comparable for demographic
data (Table-1). The objective variables for anxiety
which included VAS for anxiety, observer’s anxiety
criteria and sedation score were all significantly better
(p<0.05) in patients who received midazolam when
compared to the placebo group (Table-2). When
systolic and diastolic blood pressures were compared
between the two groups, they were significantly lower
in the midazolam group after pre-medication (p<0.05)
whereas there was no statistically significant change in
the heart rate after pre-medication in either group
(Table-3). Platelet aggregation profile was also similar
among the two groups before and after pre-medication
(Table-2).
Table-1: Demographic data
Age
Weight
Height

Group-I
Group-II
42.67±5.64
44.24±6.33
63.69±9.39
60.37±16.26
153.57±11.27
156.22±14.06
NS= not significant

p-value
NS
NS
NS

Table-2: Visual analogue, observers anxiety,
sedation score and platelet aggregation profile
Before drug
After drug
Visual Analogue Scale for Anxiety
Group I
3.49±1.51
3.50±1.33
Group II
3.06±1.34
2.01±1.38
Observer’s anxiety Criteria
Group I
1.92±0.97
1.94±0.92
Group II
1.74±0.73
1.13±0.69
Sedation Score
Group I
0.36±0.18
0.47±0.15
Group II
0.67±0.31
1.72±0.56
Platelet aggregation profile
Group I
14.51±5.68
13.75±5.96
Group II
15.35 ± 7.92
14.02 ± 6.53
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p–value
NS
<0.05
NS
<0.05
NS
<0.05
NS
NS

5

J Ayub Med Coll Abbottabad 2010;22(2)

Table-3: Haemodynamics
GROUP I
GROUP II
p–value
130.83±13.74 127.31±11.97
N.S
SBP Before drug
134.71±15.49 112.83±11.39
<0.05
SBP After drug
81.25±8.64
82.52±8.77
N.S
DBP Before drug
84.17±8.66
72.13±6.74
<0.0
DBP After drug
78.24±6.54
80.87±8.29
N.S
HR Before drug
78.31±6.32
82.32±6.58
N.S
HR After drug
SBP= Systolic blood pressure, DBP= Diastolic blood pressure,
HR= Heart Rate

DISCUSSION
Pre-medication traditionally has been used to achieve
several goals including reduction of anxiety,
preamptive
analgesia,
antisialogogue
effect,
provision of sedation etc, but the primary purpose of
prescribing these drugs in the immediate preoperative
period is to allay patient’s anxiety. Midazolam is an
imidazobenzodiazepine that is rapidly and almost
completely absorbed after oral administration.12 It has
important hypnotic with anxiolytic properties that
makes it very useful as a pre-medication drug.5 We
have performed a double blind, randomized, placebo
controlled study to assess the anxiolytic effect of
midazolam
as
pre-medication
subjectively,
objectively and biochemically. The significant
reduction in subjective assessment of anxiety level,
both by the patient and the observer, after the
administration of midazolam is in consistence with
the previous studies.9,10 Sedation was also
significantly better in the midazolam group as also
shown in previous studies. We also measured the
haemodynamic parameters including systolic blood
pressure, diastolic blood pressure and heart rate as
objective indicators of anxiolysis. In this study, there
was a statistically significant reduction in both the
systolic and diastolic blood pressures in the
midazolam group whereas the heart rate increased
clinically, but not statistically, in patients
premedicated with midazolam. Midazolam have
distinct effect on the cardiovascular system including
a decrease in myocardial contractility, systemic
vascular resistance and venodilation, all of which
result in a fall in arterial blood pressure. This fall in
systemic vascular resistance and venodilation leads to
reduction in cardiac filling pressure, which further
reduces the cardiac output. In response the
baroreceptor reflex arc is activated which causes the
heart rate to increase proportionately to compensate
for the fall in cardiac output.11 The results of our
study are consistent with previous studies6 but there
is a difference in the magnitude of heart rate effect. In
our study the rise in heart rate was less as compared
to these studies which have quoted a rise in heart rate
of up to 18%. The probable reason for this difference
could a difference in patient population and low
preoperative anxiety levels. Further studies are
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required to evaluate this effect in detail. There was no
statistically significant difference in the platelet
aggregation profile among the groups in our study
which is contrary to the results of previous studies
done on other drugs of benzodiazepine group. They
all showed an increase in platelet aggregation when
exposed to exogenous epinephrine.13,14 There are
several factors which influence the platelet
aggregation profile including age of plasma after
venipuncture, pH of plasma, platelet count of platelet
rich plasma, drugs ingested by patients, quality of
reagent and patient’s age and sex.15 Many of the
above mentioned variables were not standardised in
our study which might have affected the platelet
aggregation profile in our study. We also used sweet
syrup to dissolve placebo and midazolam which
could have resulted in a rise in serum glucose levels.
It is known that increased level of glucose increases
spontaneous platelet aggregation, independent of
other factors, therefore the results obtained in our
study may not be reflecting the true picture of platelet
aggregation.13 In this study, platelet aggregation
profile was obtained within an hour of collection of
venous blood. Hardeman14 showed transient
aggregation resistance of human blood platelets in
fresh plasma if the test is done within an hour of
venipuncture, this being another factor responsible
for adverse platelet aggregation profile.

CONCLUSION
In conclusion midazolam 0.15 mg orally one hour
before surgery is a suitable pre-medication to allay
anxiety when clinical and objective criteria are used.
The effect of midazolam on platelet aggregation
needs to be further evaluated with better controlled
trials attempting to maintain most of the variables
constant.
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